DVAX
Price
$10.27
Change
+$0.11 (+1.08%)
Updated
Jul 3 closing price
Capitalization
1.62B
27 days until earnings call
INCR
Price
$1.56
Change
+$0.08 (+5.41%)
Updated
Jul 3 closing price
Capitalization
123.5M
45 days until earnings call
Interact to see
Advertisement

DVAX vs INCR

Header iconDVAX vs INCR Comparison
Open Charts DVAX vs INCRBanner chart's image
Dynavax Technologies
Price$10.27
Change+$0.11 (+1.08%)
Volume$511.14K
Capitalization1.62B
Intercure
Price$1.56
Change+$0.08 (+5.41%)
Volume$25.22K
Capitalization123.5M
DVAX vs INCR Comparison Chart in %
Loading...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DVAX vs. INCR commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Buy and INCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (DVAX: $10.27 vs. INCR: $1.56)
Brand notoriety: DVAX and INCR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 25% vs. INCR: 201%
Market capitalization -- DVAX: $1.62B vs. INCR: $123.5M
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. INCR’s [@Pharmaceuticals: Other] market capitalization is $123.5M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 0 FA rating(s) are green whileINCR’s FA Score has 1 green FA rating(s).

  • DVAX’s FA Score: 0 green, 5 red.
  • INCR’s FA Score: 1 green, 4 red.
According to our system of comparison, INCR is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 4 TA indicator(s) are bullish while INCR’s TA Score has 4 bullish TA indicator(s).

  • DVAX’s TA Score: 4 bullish, 3 bearish.
  • INCR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than INCR.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а +3.32% price change this week, while INCR (@Pharmaceuticals: Other) price change was +4.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.13%. For the same industry, the average monthly price growth was +3.08%, and the average quarterly price growth was +93.03%.

Reported Earning Dates

DVAX is expected to report earnings on Jul 31, 2025.

INCR is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DVAX($1.62B) has a higher market cap than INCR($124M). DVAX has higher P/E ratio than INCR: DVAX (31.63) vs INCR (22.52). INCR YTD gains are higher at: -1.887 vs. DVAX (-19.577). INCR has higher annual earnings (EBITDA): 25.8M vs. DVAX (9.67M). DVAX has more cash in the bank: 742M vs. INCR (103M). INCR has less debt than DVAX: INCR (163M) vs DVAX (257M). INCR has higher revenues than DVAX: INCR (415M) vs DVAX (232M).
DVAXINCRDVAX / INCR
Capitalization1.62B124M1,307%
EBITDA9.67M25.8M37%
Gain YTD-19.577-1.8871,038%
P/E Ratio31.6322.52140%
Revenue232M415M56%
Total Cash742M103M720%
Total Debt257M163M158%
FUNDAMENTALS RATINGS
DVAX vs INCR: Fundamental Ratings
DVAX
INCR
OUTLOOK RATING
1..100
914
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
73100
SMR RATING
1..100
9393
PRICE GROWTH RATING
1..100
6362
P/E GROWTH RATING
1..100
984
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCR's Valuation (59) in the Servicestothe Health Industry industry is in the same range as DVAX (69) in the Biotechnology industry. This means that INCR’s stock grew similarly to DVAX’s over the last 12 months.

DVAX's Profit vs Risk Rating (73) in the Biotechnology industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that DVAX’s stock grew similarly to INCR’s over the last 12 months.

DVAX's SMR Rating (93) in the Biotechnology industry is in the same range as INCR (93) in the Servicestothe Health Industry industry. This means that DVAX’s stock grew similarly to INCR’s over the last 12 months.

INCR's Price Growth Rating (62) in the Servicestothe Health Industry industry is in the same range as DVAX (63) in the Biotechnology industry. This means that INCR’s stock grew similarly to DVAX’s over the last 12 months.

INCR's P/E Growth Rating (4) in the Servicestothe Health Industry industry is significantly better than the same rating for DVAX (98) in the Biotechnology industry. This means that INCR’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXINCR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 12 days ago
71%
Declines
ODDS (%)
Bearish Trend 12 days ago
80%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LAVVX16.26N/A
N/A
Lord Abbett Fundamental Equity R6
STSAX7.19N/A
N/A
Allspring Common Stock C
JVACX39.03N/A
N/A
JPMorgan Value Advantage C
MADSX28.64N/A
N/A
Morgan Stanley Inst Advantage R6
GSAFX24.54N/A
N/A
Goldman Sachs China Equity R6

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
+1.08%
ACET - DVAX
39%
Loosely correlated
-1.14%
SNDL - DVAX
35%
Loosely correlated
+1.60%
ESPR - DVAX
34%
Loosely correlated
+1.74%
SUPN - DVAX
34%
Loosely correlated
-0.28%
ALKS - DVAX
33%
Loosely correlated
-0.52%
More

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and SNDL have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and SNDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
+5.41%
SNDL - INCR
25%
Poorly correlated
+1.60%
KMDA - INCR
24%
Poorly correlated
+1.81%
ACB - INCR
24%
Poorly correlated
+1.57%
OGI - INCR
24%
Poorly correlated
+3.62%
DVAX - INCR
23%
Poorly correlated
+1.08%
More